Description: Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50 percent of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke was launched with investments by Apple Tree Partners. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
Home Page: www.stoketherapeutics.com
STOK Technical Analysis
45 Wiggins Avenue
Bedford,
MA
01730
United States
Phone:
781 430 8200
Officers
| Name | Title |
|---|---|
| Dr. Edward M. Kaye M.D., Ph.D. | CEO & Director |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board |
| Mr. Stephen J. Tulipano CPA, CPA, MBA | Chief Financial Officer |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer |
| Ms. Isabel Aznarez Ph.D. | Co-Founder & Group VP of Discovery Research |
| Dr. Huw M. Nash Ph.D. | COO & Chief Bus. Officer |
| Mr. Eric Rojas | Head of Investor Relations |
| Mr. Jonathan Allan J.D. | Gen. Counsel |
| Ms. Dawn Kalmar | Chief Communications Officer |
| Ms. Joan Wood | Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6186 |
| Price-to-Sales TTM: | 35.8186 |
| IPO Date: | 2019-06-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 102 |